# Effect of Hyperuricaemia on Chronic Renal Disease

Study · id `cardio:ct-nct03425708` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03425708](<https://clinicaltrials.gov/study/NCT03425708>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03425708

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT03425708. Randomized; single masking; primary purpose treatment. Start 2017-01-01 (actual); primary completion 2018-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT03425708, source copy `cardio:ctgov-nct03425708-2018-02-07`, retrieved 2026-10-26)
- Started: 2017-01-01 (actual) (ClinicalTrials.gov record NCT03425708, source copy `cardio:ctgov-nct03425708-2018-02-07`, retrieved 2026-10-26)
- Primary completion: 2018-12-31 (anticipated) (ClinicalTrials.gov record NCT03425708, source copy `cardio:ctgov-nct03425708-2018-02-07`, retrieved 2026-10-26)
- Completion: 2018-12-31 (anticipated) (ClinicalTrials.gov record NCT03425708, source copy `cardio:ctgov-nct03425708-2018-02-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03425708, source copy `cardio:ctgov-nct03425708-2018-02-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03425708-2018-02-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Hyperuricaemia on Chronic Renal Disease
- Condition: Hyperuricemia
- Condition: Chronic Renal Disease
- Intervention (Drug): 20mg Febuxostat
- Intervention (Drug): 40mg Febuxostat
- Lead sponsor: The Affiliated Hospital of Xuzhou Medical University
- Lead sponsor class: OTHER
- Collaborator: The First People's Hospital of Xuzhou
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: The Affiliated Hospital of Xuzhou Medical University (`cardio:org-the-affiliated-hospital-of-xuzhou-medical-university`)

## Provenance

Content hash: fc73c4bbd3e12f7b4110a312a95922f76f59007ed0a37bd9b8d80d6c6b4fff44
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
